Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA
復星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The following sets out the "Announcement in Relation to the Approval of Drug Clinical Trial of a Subsidiary" published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "**Company**") on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the above mentioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Yuqing
Chairman

Shanghai, the PRC
16 November 2026

As at the date of this announcement, the executive directors of the Company are Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wen Deyong, Mr. Wang Kexin and Mr. Liu Yi; the non-executive directors of the Company are Mr. Chen Qiyu and Mr. Pan Donghui; the independent non-executive directors of the Company are Mr. Yu Tze Shan Hailson, Mr. Wang Quandi, Mr. Chen Penghui and Mr. Yang Yucheng; and the employee director of the Company is Ms. Yan Jia.

* *for identification purposes only*

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Announcement in Relation to the Approval of Drug Clinical Trial of a Subsidiary

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein contained.

I. Overview

Recently, Chengdu StarRay Therapeutics Company Limited* (成都星睿菁烜生物科技有限公司) ("**StarRay**"), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (上海復星醫藥（集團）股份有限公司) (the "**Company**") received the approval from the National Medical Products Administration for the clinical trial of [^{18}F]F-SR031 Injection ("**SRT-003-1**") for positron emission tomography ("**PET**") imaging of fibroblast activation protein ("**FAP**")-positive lesions in patients with solid tumors. StarRay intends to commence the Phase I clinical trial of the drug in Chinese mainland[1] when the conditions are fulfilled.

II. Basic Information and Development Progress on SRT-003-1

SRT-003-1 is a radiopharmaceutical in vivo diagnostic drug targeting FAP, intended primarily for PET imaging of FAP-positive lesions in patients with solid tumors. FAP is a type II transmembrane serine protease belonging to the prolyl oligopeptidase family. It is essentially absent from normal tissues, but selectively overexpressed in cancer-associated fibroblasts (CAFs) within a variety of epithelial tumors, including gastric, esophageal, lung, colorectal, and ovarian cancer. An FAP inhibitor labeled with fluorine-18 ([^{18}F]) can specifically bind to FAP on the surface of CAFs, resulting in high uptake within

[1] Excluding Hong Kong, Macau and Taiwan regions for the purpose of this announcement, the same applies below.

FAP-overexpressing tumor lesions on PET imaging, thereby enabling tumor diagnosis, staging, and psot-treatment efficacy evaluation.

As of October 2026, the Group (i.e., the Company and its subsidiaries/units) has invested approximately RMB25 million (unaudited) in total in the research and development of SRT-003-1 up to this stage.

As of the date of this announcement (i.e. 16 November 2026), no FAP-targeted radiopharmaceutical diagnostic drug has been approved for launch in Chinese mainland.

III. Risk Reminder

As required by the relevant regulations, SRT-003-1 is still required to undergo relevant clinical trials in Chinese mainland and obtain approval from the national drug review authority before it can be launched.

The process from drug development and clinical research to launch involves a long period and multiple stages, with various uncertainties. Investors should take note of the investment risks.

Announcement is hereby made.

Board of Directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

16 November 2026

*For identification purpose only